177 related articles for article (PubMed ID: 9438228)
1. Reboxetine: additional benefits to the depressed patient.
Montgomery SA
J Psychopharmacol; 1997; 11(4 Suppl):S9-15. PubMed ID: 9438228
[TBL] [Abstract][Full Text] [Related]
2. Chairman's overview. The place of reboxetine in antidepressant therapy.
Montgomery SA
J Clin Psychiatry; 1998; 59 Suppl 14():26-9. PubMed ID: 9818628
[TBL] [Abstract][Full Text] [Related]
3. Reboxetine: a review of antidepressant tolerability.
Mucci M
J Psychopharmacol; 1997; 11(4 Suppl):S33-7. PubMed ID: 9438231
[TBL] [Abstract][Full Text] [Related]
4. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review.
Burrows GD; Maguire KP; Norman TR
J Clin Psychiatry; 1998; 59 Suppl 14():4-7. PubMed ID: 9818623
[TBL] [Abstract][Full Text] [Related]
5. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning.
Dubini A; Bosc M; Polin V
J Psychopharmacol; 1997; 11(4 Suppl):S17-23. PubMed ID: 9438229
[TBL] [Abstract][Full Text] [Related]
6. Reboxetine--another new antidepressant.
Drug Ther Bull; 1998 Nov; 36(11):86-8. PubMed ID: 10562766
[TBL] [Abstract][Full Text] [Related]
7. Reboxetine, the first selective noradrenaline reuptake inhibitor antidepressant: Efficacy and tolerability in 2613 patients.
Versiani M
Int J Psychiatry Clin Pract; 2000; 4(3):201-8. PubMed ID: 24927454
[TBL] [Abstract][Full Text] [Related]
8. Reboxetine: the first selective noradrenaline re-uptake inhibitor.
Kasper S; el Giamal N; Hilger E
Expert Opin Pharmacother; 2000 May; 1(4):771-82. PubMed ID: 11249515
[TBL] [Abstract][Full Text] [Related]
9. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
Baldwin D; Bridgman K; Buis C
J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
[TBL] [Abstract][Full Text] [Related]
10. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up.
Fruehwald S; Gatterbauer E; Rehak P; Baumhackl U
J Neurol; 2003 Mar; 250(3):347-51. PubMed ID: 12638027
[TBL] [Abstract][Full Text] [Related]
11. Use of reboxetine in bulimia nervosa: a pilot study.
Fassino S; Daga GA; Boggio S; Garzaro L; Pierò A
J Psychopharmacol; 2004 Sep; 18(3):423-8. PubMed ID: 15358988
[TBL] [Abstract][Full Text] [Related]
12. Predicting response: noradrenaline reuptake inhibition.
Montgomery SA
Int Clin Psychopharmacol; 1999 May; 14 Suppl 1():S21-6. PubMed ID: 10468325
[TBL] [Abstract][Full Text] [Related]
13. Reboxetine versus fluoxetine: an overview of efficacy and tolerability.
Massana J
J Clin Psychiatry; 1998; 59 Suppl 14():8-10. PubMed ID: 9818624
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of reboxetine as an antidepressant, a meta-analysis of both continuous (mean HAM-D score) and dichotomous (response rate) outcomes.
Chuluunkhuu G; Nakahara N; Yanagisawa S; Kamae I
Kobe J Med Sci; 2008 Jul; 54(2):E147-58. PubMed ID: 18772616
[TBL] [Abstract][Full Text] [Related]
15. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder.
Clayton AH; Zajecka J; Ferguson JM; Filipiak-Reisner JK; Brown MT; Schwartz GE
Int Clin Psychopharmacol; 2003 May; 18(3):151-6. PubMed ID: 12702894
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
Langworth S; Bodlund O; Agren H
J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression. A random, placebo-controlled study.
Rampello L; Alvano A; Chiechio S; Raffaele R; Vecchio I; Malaguarnera M
Arch Gerontol Geriatr; 2005; 40(3):275-85. PubMed ID: 15814161
[TBL] [Abstract][Full Text] [Related]
18. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
Fava M; McGrath PJ; Sheu WP;
J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
[TBL] [Abstract][Full Text] [Related]
19. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.
Versiani M; Mehilane L; Gaszner P; Arnaud-Castiglioni R
J Clin Psychiatry; 1999 Jun; 60(6):400-6. PubMed ID: 10401920
[TBL] [Abstract][Full Text] [Related]
20. Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial.
Spivak B; Strous RD; Shaked G; Shabash E; Kotler M; Weizman A
J Clin Psychopharmacol; 2006 Apr; 26(2):152-6. PubMed ID: 16633143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
